Identification of Potential Drug Interactions of Patients with Chronic Kidney Disease Based on Lexicomp® Application

One of the factors that cause chronic kidney disease is comorbid diseases. Comorbidities can lead to polypharmacy, which can increase the potential for drug interactions. Potential drug interactions, if not addressed, can increase the incidence of morbidity and mortality. The purpose of the study was to identify potential drug interactions with drugs for patients with chronic kidney disease using the Lexicomp® application in terms of risk level, severity, and recommendations for the treatment of drug interactions. The study was conducted at Ansari Saleh Hospital, Banjarmasin, from January to February 2024. The study sample consisted of 58 patients. Data were analyzed using the Lexicomp® application. The results showed that 56.90% of the patients had potential drug interactions, with 175 cases of potential drug interactions in 53 drug combinations. The percentage of potential drug interactions based on risk level was 31.43% (category B), 61.71% (category C), 4% (category D), and 2.86% (category X). The percentage of potential drug interactions according to severity was 33.71% (minor), 62.29% (moderate), and 4% (major). Treatment recommendations for drug interactions with drugs include not need for action, monitoring therapy, and dose adjustment. Potential drug interactions with drugs for patients with chronic kidney disease using the Lexicomp® application in terms of the majority of risk levels in category C, the severity of most moderate categories, and recommendations for handling drug interactions for the majority need to monitor therapy and dose adjustments. Chronic kidney disease patients have the potential to experience moderate drug-drug interactions of the category, with treatment recommendations that require therapeutic monitoring.